GlassScriptPhysician profile
Neha Hingorani
NPI 1053775023
$991.05
in general payments reported to CMS, 2019-2025
11 companies · $527 in 2025
The $527 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $104 · 2023: $131 · 2024: $104 · 2025: $527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $762.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $761.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $125.40 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $125.00 | 2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2021 | |
| Lilly USA, LLC | $124.99 | 2025 | Omvoh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $106.36 | 2023-2025 | Xifaxan |
| Ge Healthcare | $104.19 | 2022 | |
| Merck Sharp & Dohme LLC | $85.25 | 2023-2024 | Dificid |
| Incyte Corporation | $75.03 | 2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $57.95 | 2025 | Dupixent |
| Gilead Sciences, INC. | $38.45 | 2023-2024 | |
| Abbvie INC. | $23.43 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neha Hingorani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.